JP2013515745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515745A5 JP2013515745A5 JP2012546245A JP2012546245A JP2013515745A5 JP 2013515745 A5 JP2013515745 A5 JP 2013515745A5 JP 2012546245 A JP2012546245 A JP 2012546245A JP 2012546245 A JP2012546245 A JP 2012546245A JP 2013515745 A5 JP2013515745 A5 JP 2013515745A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- amino acids
- amino acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 137
- 150000001413 amino acids Chemical class 0.000 claims description 80
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 108090000663 Annexin A1 Proteins 0.000 claims description 7
- 102100040006 Annexin A1 Human genes 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 239000002078 nanoshell Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 102000000412 Annexin Human genes 0.000 claims 1
- 108050008874 Annexin Proteins 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- -1 binding tag Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28983309P | 2009-12-23 | 2009-12-23 | |
| US61/289,833 | 2009-12-23 | ||
| PCT/US2010/062072 WO2011079304A1 (en) | 2009-12-23 | 2010-12-23 | Methods and compositions related to annexin 1-binding compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015051656A Division JP6331030B2 (ja) | 2009-12-23 | 2015-03-16 | アネキシン１結合化合物に関する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515745A JP2013515745A (ja) | 2013-05-09 |
| JP2013515745A5 true JP2013515745A5 (OSRAM) | 2013-12-12 |
| JP6184101B2 JP6184101B2 (ja) | 2017-08-23 |
Family
ID=43923683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546245A Active JP6184101B2 (ja) | 2009-12-23 | 2010-12-23 | アネキシン１結合化合物に関する方法および組成物 |
| JP2015051656A Active JP6331030B2 (ja) | 2009-12-23 | 2015-03-16 | アネキシン１結合化合物に関する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015051656A Active JP6331030B2 (ja) | 2009-12-23 | 2015-03-16 | アネキシン１結合化合物に関する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9610359B2 (OSRAM) |
| EP (1) | EP2515944B1 (OSRAM) |
| JP (2) | JP6184101B2 (OSRAM) |
| CA (1) | CA2784645C (OSRAM) |
| SG (2) | SG10201704812TA (OSRAM) |
| WO (1) | WO2011079304A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10030036B2 (en) * | 2009-05-15 | 2018-07-24 | Lahjavida, Llc | Method and dyes for detecting and destroying cancer cells |
| CN102898527B (zh) * | 2011-07-25 | 2016-12-21 | 三星电子株式会社 | 融合蛋白、药物组合物及预防或治疗癌症的方法 |
| SI3468621T1 (sl) * | 2016-06-10 | 2023-01-31 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Jedrna domena aneksinov in uporabe le-teh pri odmerjanju antigena in cepljenju |
| PH12019500306B1 (en) * | 2016-08-16 | 2024-02-21 | Aist | Malignant tumor target peptide |
| JP2019532104A (ja) * | 2016-09-30 | 2019-11-07 | アイエフセブンキュアー, インコーポレイテッドIf7Cure, Inc | 腫瘍血管系を標的とする抗腫瘍剤の製造方法 |
| JP6856227B2 (ja) * | 2017-02-09 | 2021-04-07 | 株式会社Ｃｉｃｓ | 計測装置 |
| JP6613499B2 (ja) | 2017-08-24 | 2019-12-04 | 学校法人藤田学園 | 細胞殺傷剤 |
| WO2019138944A1 (ja) * | 2018-01-09 | 2019-07-18 | 学校法人藤田学園 | 細胞殺傷剤 |
| US20210292400A1 (en) * | 2018-05-17 | 2021-09-23 | Yiping W. Han | Methods for treating, preventing and detecting the prognosis of colorectal cancer |
| EP3811980A4 (en) * | 2018-06-20 | 2022-04-13 | Hirosaki University | Accumulative boron 10 medicine for boron neutron capture therapy for selectively or locally targeting tumor tissues in short time |
| JP7224628B2 (ja) * | 2019-02-01 | 2023-02-20 | 国立研究開発法人産業技術総合研究所 | 抗ｍｃ１６抗体 |
| US12109276B2 (en) | 2019-03-15 | 2024-10-08 | Lahjavida, Llc | Near-infrared dyes and conjugates for targeting tumors |
| JP2022525791A (ja) * | 2019-03-26 | 2022-05-19 | 株式会社島津製作所 | 光免疫療法およびそれに用いる薬剤 |
| CN111120645B (zh) * | 2019-12-30 | 2021-10-08 | 潍柴动力股份有限公司 | 一种挡位控制方法、装置及电子设备 |
| US12370266B2 (en) | 2022-09-13 | 2025-07-29 | Core Quantum, Inc. | Polymer composite nanomaterial encapsulation system |
| CN116199748B (zh) * | 2023-01-16 | 2025-08-05 | 中国地质大学（武汉） | 多肽荧光探针及其在检测活细胞内聚集蛋白中的应用 |
| CN116606351B (zh) * | 2023-04-17 | 2025-04-18 | 合肥师范学院 | 一种基于理性分子设计构建的抗菌肽hsp-m4及制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1016978B (de) | 1955-05-16 | 1957-10-03 | Iashellia Res Ltd | Mittel zur Bekaempfung des Pflanzenwachstums |
| CH588887A5 (OSRAM) | 1974-07-19 | 1977-06-15 | Battelle Memorial Institute | |
| JPS5186117A (en) | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4418052A (en) | 1980-08-12 | 1983-11-29 | Wong Dennis W | Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4761288A (en) | 1984-09-24 | 1988-08-02 | Mezei Associates Limited | Multiphase liposomal drug delivery system |
| US5628936A (en) | 1987-03-13 | 1997-05-13 | Micro-Pak, Inc. | Hybrid paucilamellar lipid vesicles |
| US5474848A (en) | 1987-03-13 | 1995-12-12 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4853228A (en) | 1987-07-28 | 1989-08-01 | Micro-Pak, Inc. | Method of manufacturing unilamellar lipid vesicles |
| US5011686A (en) | 1987-09-21 | 1991-04-30 | Creative Biomolecules, Inc. | Thrombus specific conjugates |
| US5013497A (en) | 1988-03-03 | 1991-05-07 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
| US5024829A (en) | 1988-11-21 | 1991-06-18 | Centocor, Inc. | Method of imaging coronary thrombi |
| US5643873A (en) * | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
| EP0706374B1 (en) | 1993-06-30 | 1997-12-10 | Genentech, Inc. | Method for preparing liposomes |
| US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5897945A (en) | 1996-02-26 | 1999-04-27 | President And Fellows Of Harvard College | Metal oxide nanorods |
| US6506564B1 (en) | 1996-07-29 | 2003-01-14 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| GB9708265D0 (en) | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| PL344749A1 (en) | 1998-06-11 | 2001-11-19 | Dimensional Pharmaceuticals 3 | Pyrazinone protease inhibitors |
| US6451969B1 (en) * | 1999-01-15 | 2002-09-17 | The Burnham Institute | Methods for inhibiting tumor metastasis, and peptides useful therfor |
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| US20040037775A1 (en) * | 2000-08-01 | 2004-02-26 | Siahaan Teruna J. | Leukocyte internalized peptide-drug conjugates |
| CA2430562C (en) | 2000-11-30 | 2010-02-02 | The Penn State Research Foundation | Dna methyl transferase inhibitors |
| DE60318466T2 (de) * | 2002-09-27 | 2008-09-18 | Nihon Medi-Physics Co., Ltd. | An leukozyten bindende verbindung und diese verbindung im markierten zustand als wirkstoff enthaltende medizinische zusammensetzung |
-
2010
- 2010-12-23 SG SG10201704812TA patent/SG10201704812TA/en unknown
- 2010-12-23 EP EP10803326.7A patent/EP2515944B1/en active Active
- 2010-12-23 WO PCT/US2010/062072 patent/WO2011079304A1/en not_active Ceased
- 2010-12-23 SG SG2012046652A patent/SG181899A1/en unknown
- 2010-12-23 US US13/515,930 patent/US9610359B2/en active Active
- 2010-12-23 JP JP2012546245A patent/JP6184101B2/ja active Active
- 2010-12-23 CA CA2784645A patent/CA2784645C/en active Active
-
2015
- 2015-03-16 JP JP2015051656A patent/JP6331030B2/ja active Active
-
2017
- 2017-04-04 US US15/478,699 patent/US20170326245A1/en not_active Abandoned
-
2021
- 2021-04-26 US US17/240,714 patent/US20210260202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515745A5 (OSRAM) | ||
| JP2013513377A5 (OSRAM) | ||
| JP2017523781A5 (OSRAM) | ||
| JP2015522264A5 (OSRAM) | ||
| WO2011157713A3 (en) | Cell-penetrating peptides and uses therof | |
| JP2012255007A5 (OSRAM) | ||
| MY155029A (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| Sadeqzadeh et al. | Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells | |
| JP2016527286A5 (OSRAM) | ||
| CA2994279A1 (en) | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same | |
| JP2014526881A5 (OSRAM) | ||
| JP2019534884A5 (OSRAM) | ||
| JP2016531583A5 (OSRAM) | ||
| JP2019524871A5 (OSRAM) | ||
| JP2019537600A5 (OSRAM) | ||
| JP2019537562A5 (OSRAM) | ||
| WO2016168578A1 (en) | siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER | |
| Mollaei et al. | A brief review of exosomes and their roles in cancer | |
| CN108578369A (zh) | 表面双修饰的靶向人血清白蛋白纳米药物载体的制备与应用 | |
| Pechar et al. | Polymer cancerostatics targeted with an antibody fragment bound via a coiled coil motif: In vivo therapeutic efficacy against murine BCL1 leukemia | |
| JP2023503797A (ja) | 分子ガイドシステムペプチド及びその使用 | |
| CN104311672B (zh) | 一种具有肿瘤细胞靶向性的抑制剂多肽 | |
| Ng et al. | The potential use of anticancer peptides (ACPs) in the treatment of hepatocellular carcinoma | |
| Li et al. | Polyethylene Glycolylation of the Purified Basic Protein (Protamine) of Squid (Symplectoteuthis oualaniensis): Structural Changes and Evaluation of Proliferative Effects on Fibroblast | |
| Liao et al. | Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives |